Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 501–600 of 1,017
Nam, K. H., Chang, T. I., Joo, Y. S., Kim, J., Lee, S., Lee, C., Yun, H., Park, J. T., Yoo, T., Sung, S. A., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011162 · Cited by 78
HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
Kjeldsen, E. W., Nordestgaard, L. T., & Frikke‐Schmidt, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094547 · Cited by 80
Gordon, S. M., Deng, J., Tomann, A. B., Shah, A. S., Lu, L. J., & Davidson, W. S. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.028134 · Cited by 72
“The recent failures of niacin (5) and two different cholesteryl ester transfer protein inhibitors (6, 7), all capable of significantly raising HDL cholesterol levels, have cast doubt on the idea that raising HDL cholesterol in the generic sense can translate to protection against CVD predicted from observational epide…”
BackgroundBrinck, J. W., Thomas, A., Lauer, E., Jornayvaz, F. R., Brulhart‐Meynet, M., Prost, J., Pataky, Z., Löfgren, P., Hoffstedt, J., Eriksson, M., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.307049 · Cited by 76
Self-citationVisconti, L., Benvenga, S., Lacquaniti, A., Cernaro, V., Bruzzese, A., Conti, G., Buemi, M., & Santoro, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.002 · Cited by 82
“The phase 3 trial with torcetrapib, the first CEPT inhibitor, was interrupted due to the high mortality rate in the treated group [72].”
BackgroundKhoudary, S. R. E., Wang, L., Brooks, M. M., Thurston, R. C., Derby, C. A., & Matthews, K. A. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.008 · Cited by 76
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Table 2 Beta Coefficients for the Interactions of Baseline HDL-C and Change in HDL-C and time Relative to FMP on Carotid Intima-Media Thickness, N=212 women / 525 observations HDL-C Measures Progression in cIMT, mm/year β (SE)a P value Mod…”
BackgroundInfluentialPeripheral Blood Monocyte Sirt1 Expression Is Reduced in Patients with Coronary Artery Disease
Breitenstein, A., Wyss, C. A., Spescha, R. D., Franzeck, F. C., Hof, D., Riwanto, M., Hasun, M., Akhmedov, A., von Eckardstein, A., Maier, W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053106 · Cited by 73
“Indeed, epidemiologically HDL plasma levels are inversely related to myocardial infarction and stroke even in patients treated with a statin [14].”
Familial hypercholesterolemia: current treatment and advances in management
Huijgen, R., Vissers, M. N., Defesche, J. C., Lansberg, P. J., Kastelein, J. J., & Hutten, B. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.4.567 · Cited by 71
Self-citationTriolo, M., Annema, W., Dullaart, R. P. F., & Tietge, U. J. F. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.35 · Cited by 74
Siebel, A. L., Natoli, A. K., Yap, F. Y. T., Carey, A. L., Reddy-Luthmoodoo, M., Sviridov, D., Weber, C. I. K., Meneses-Lorente, G., Maugeais, C., Forbes, J. M., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.300689 · Cited by 71
High-density lipoprotein cholesterol in diabetes: Is higher always better?
Costacou, T., Evans, R. W., & Orchard, T. J. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.06.011 · Cited by 71
“Indeed, achieving higher plasma HDL-C concentrations via blockage of the cholesteryl ester transfer protein resulted in an increased (not decreased) risk of all cause mortality and cardiovascular morbidity in the ILLUMINATE trial (1) and failed to slow atherosclerosis progression in another two clinical trials (2, 3).”
BackgroundTransforming the critique of Big Pharma
Pollock, A. (2011) · BioSocieties · doi:10.1057/biosoc.2010.44 · Cited by 77
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 76
Chen, S., & Cheng, W. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.895499 · Cited by 99
Regression of Atherosclerosis: Insights from Animal and Clinical Studies
Feig, J. E. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.001 · Cited by 78
Smith, C. J., Ali, A., Hammond, M. L., Li, H., Lu, Z., Napolitano, J. B., Taylor, G. E., Thompson, C. F., Anderson, M. S., Chen, Y., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200484c · Cited by 76
Francis, G. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.08.009 · Cited by 83
Current and future trends in the lipid lowering therapy
Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 72
“Large-scale trials were initiated, but results of the first (ILLUMINATE) with torcetrapib showed harm compared to placebo [70].”
BackgroundEffects of bariatric surgery on lipid-lipoprotein profile
Piché, M., Tardif, I., Auclair, A., & Poirier, P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154441 · Cited by 77
Nelson, A. J., Sniderman, A. D., Ditmarsch, M., Dicklin, M. R., Nicholls, S. J., Davidson, M. H., & Kastelein, J. J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169417 · Cited by 67
“This includes the cardiovascular outcome trials of the first CETP inhibitors, torcetrapib, dalcetrapib (CETP modulator/functional CETP inhibitor), and evacetrapib, which all failed to reduce ASCVD risk for a variety of agent-specific reasons [3,16,17].”
BackgroundSelf-citationWhole genome sequence analysis of blood lipid levels in >66,000 individuals
Selvaraj, M. S., Li, X., Li, Z., Pampana, A., Zhang, D. Y., Park, J., Aslibekyan, S., Bis, J. C., Brody, J. A., Cade, B. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33510-7 · Cited by 69
HDL Functions—Current Status and Future Perspectives
Endo, Y., Fujita, M., & Ikewaki, K. (2023) · Biomolecules · doi:10.3390/biom13010105 · Cited by 84
“Furthermore, CETP inhibitors, potent HDL-Craising drugs, failed to show a protective effect against the development of CVD [2,4,5].”
Gilbert, O. N., Croffoot, J. R., Taylor, A. J., Nash, M. S., Schomer, K. G., & Groah, S. L. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.11.028 · Cited by 82
Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac Fibrosis
Busseuil, D., Shi, Y., Mecteau, M., Brand, G., Gillis, M., Thorin, É., Asselin, C., Roméo, P., Leung, T. K., Latour, J.-G., et al. (2010) · Cardiology · doi:10.1159/000322905 · Cited by 75
“our observation of reduced atrial and ventricular fibrosis induced by IVA in the setting of dyslipidemia-induced DD potentially opens a new area of investigation for the prevention of this common arrhythmia. Moreover, plasma levels of angiotensin II and aldosterone were positively correlated with HR during treatment i…”
ResultSelf-citationRisk Factor Management to Prevent First Stroke
Rundek, T., & Sacco, R. L. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.09.001 · Cited by 83
“More importantly, increased cardiovascular morbidity and mortality, despite achieving an aggressive reduction in LDL cholesterol and increased HDL cholesterol, was reported [67,83,84].”
Calabresi, L., Simonelli, S., Conca, P., Busnach, G., Cabibbe, M., Gesualdo, L., Gigante, M., Penco, S., Veglia, F., & Franceschini, G. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12290 · Cited by 71
Bochem, A. E., van Wijk, D. F., Holleboom, A. G., Duivenvoorden, R., Motazacker, M. M., Dallinga-Thie, G. M., de Groot, E., Kastelein, J. J. P., Nederveen, A. J., Hovingh, G. K., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs376 · Cited by 67
Self-citationFuture of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective
Mohammadpour, A. H., & Akhlaghi, F. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0071-8 · Cited by 69
“patient group with a higher increase in HDL-C and apoA-1 [37].”
InfluentialHDL and Cardiovascular Risk: Time to Call the Plumber?
Hewing, B., Moore, K. J., & Fisher, E. A. A. (2012) · Circulation Research · doi:10.1161/circresaha.112.280958 · Cited by 67
“A ray of hope for the HDL-C protection concept came from a post hoc analysis of ILLUMINATE, which showed that cardiovascular events were lower in the torcetrapib-treated group with the highest increases in HDL-C and apoA-I.(4) The issue of whether cholesteryl ester transfer protein inhibitors can be useful clinical th…”
ResultGrover, S. A., Kaouache, M., Joseph, L., Barter, P., & Davignon, J. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.328 · Cited by 69
“Average b treated HDL-C level, mg/dLa 41 (11) 40 (10) 44 (10) 53 ( 13 )”
Self-citationHDL-replacement therapy: mechanism of action, types of agents and potential clinical indications
Remaley, A. T., Amar, M., & Sviridov, D. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.9.1203 · Cited by 69
“99, 1031–1043 (2006). Cavelier C, Lorenzi I, Rohrer L, 20”
BackgroundInfluentialCupido, A. J., Reeskamp, L. F., Hingorani, A. D., Finan, C., Asselbergs, F. W., Hovingh, G. K., & Schmidt, A. F. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2333 · Cited by 68
Michos, E. D., Sibley, C. T., Baer, J., Blaha, M. J., & Blumenthal, R. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.045 · Cited by 68
Challenging Issues in Clinical Trial Design
Pocock, S., Clayton, T. C., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.051 · Cited by 77
“007), which was the prime reason for stopping the trial for harm (49).”
BackgroundLandray, M. J., & REVEAL Collaborative Group (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.021 · Cited by 68
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Kastelein, J. J. P., Hsieh, A., Dicklin, M. R., Ditmarsch, M., & Davidson, M. H. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01184-1 · Cited by 68
“…torcetrapib, increased the risks of cardiovascular events and death in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, which led to the trial’s premature termination and discontinuation of the development of torcetrapib [22].”
BackgroundSelf-citationType 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 76
Mendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 68
Drug-related hypertension and resistance to antihypertensive treatment: a call for action
Rossi, G. P., Seccia, T. M., Maniero, C., & Pessina, A. C. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834c465d · Cited by 68
Chang, T. I., Streja, E., Soohoo, M., Kim, T., Rhee, C. M., Kovesdy, C. P., Kashyap, M. L., Vaziri, N. D., Kalantar‐Zadeh, K., & Moradi, H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08730816 · Cited by 77
Rethinking good cholesterol: a clinicians' guide to understanding HDL
Xiang, A. S., & Kingwell, B. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30003-8 · Cited by 75
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Barylski, M., Toth, P. P., Nikolic, D., Banach, M., Rizzo, M., & Montalto, G. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.11.001 · Cited by 67
Nonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 73
“001).(113) Similar to previous trials, significant increases in systolic blood pressure were found (5.”
ResultThe effects of apolipoprotein B depletion on HDL subspecies composition and function
Davidson, W. S., Heink, A., Sexmith, H., Melchior, J., Gordon, S. M., Kuklenyik, Z., Woollett, L. A., Barr, J. R., Jones, J. I., Toth, C. A., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066613 · Cited by 72
Xu, Z., Xie, J., Zhang, H., Pang, J., Li, Q., Wang, X., Xu, H., Sun, X., Zhao, H. W., Yang, Y., et al. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0609-4 · Cited by 70
Miyamoto–Sasaki, M., Yasuda, T., Monguchi, T., Nakajima, H., Mori, K., Toh, R., Ishida, T., & Hirata, K. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.17210 · Cited by 67
Proteomics Investigations of HDL: Challenges and Promise
Vaisar, T. (2012) · Current Vascular Pharmacology · doi:10.2174/157016112800812755 · Cited by 77
“For example, genetic variations that associate with altered HDL-C do not strongly associate with altered CVD risk,[26] certain drugs that elevate HDL levels, such as fibric acid derivatives, show no clear clinical benefit,[27] , a cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, that increased HDL-C b…”
BackgroundShould low high-density lipoprotein cholesterol (HDL-C) be treated?
Toth, P. P., Barylski, M., Nikolić, D., Rizzo, M., Montalto, G., & Banach, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.11.002 · Cited by 73
Papp, A. C., Pinsonneault, J. K., Wang, D., Newman, L. C., Gong, Y., Johnson, J. A., Pepine, C. J., Meena Kumari, B., Hingorani, A. D., Talmud, P. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031930 · Cited by 69
“The results reported here support CETP variants as a potential disease markers and predictor of statin therapy outcome, and in evaluating CETP inhibitor drugs, such as torcetrapib [3], in the treatment of coronary artery disease.”
BackgroundResultThe Therapeutic Role of Niacin in Dyslipidemia Management
Boden, W. E., Sidhu, M. S., & Toth, P. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413514481 · Cited by 74
HDL and atherosclerosis: Insights from inherited HDL disorders
Calabresi, L., Gomaraschi, M., Simonelli, S., Bernini, F., & Franceschini, G. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.07.015 · Cited by 75
Tardif, J., Rhainds, D., Brodeur, M. R., Zada, Y. F., Fouodjio, R., Provost, S., Boulé, M., Alem, S., Grégoire, J. C., L’Allier, P. L., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001405 · Cited by 73
“This contrasts with the failure of torcetrapib and evacetrapib, as well as that of dalcetrapib in GG patients.(4,6,16) Interestingly, CETP inhibitors have been shown to raise the level of hs-CRP.”
ResultSelf-citationDeficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits
Zhang, J., Niimi, M., Yang, D., Liang, J., Xu, J., Kimura, T., Mathew, A. V., Guo, Y., Fan, Y., Zhu, T., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309114 · Cited by 69
Unravelling HDL—Looking beyond the Cholesterol Surface to the Quality Within
Kajani, S., Curley, S., & McGillicuddy, F. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071971 · Cited by 75
“4 mmHg) through activation of the renin–angiotensin–aldosterone system [13].”
BackgroundZhu, L., Shi, J., Luu, T. N., Neuman, J. C., Trefts, E., Yu, S., Palmisano, B. T., Wasserman, D. H., Linton, M. F., & Stafford, J. M. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2017.12.012 · Cited by 66
Imaging Biomarkers in Atherosclerosis Trials
Tardif, J., Lesage, F., Harel, F., Roméo, P., & Pressacco, J. (2011) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.962001 · Cited by 73
Self-citationFuture of Cholesteryl Ester Transfer Protein Inhibitors
Rader, D. J., & deGoma, E. M. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-163305 · Cited by 66
“Extrapolating from these data and human genetic studies of CETP deficiency, the magnitude of the lipid changes achieved with torcetrapib 60 mg daily was hypothesized to translate into at least a 20% reduction in cardiovascular events (9).”
InfluentialTriglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent
Semova, I., & Biddinger, S. B. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.12.001 · Cited by 75
Dietary guidelines for saturated fatty acids are not supported by the evidence
Parodi, P. W. (2015) · International Dairy Journal · doi:10.1016/j.idairyj.2015.08.007 · Cited by 75
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
Burnett, J., Bell, Hooper, & Watts (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28581 · Cited by 64
“Torcetrapib, the first CETP inhibitor to be studied in a Phase III trial, was discontinued due to a number of off-target side effects, namely elevations in systolic blood pressure and increases in plasma aldosterone, sodium, and bicarbonate, and reductions in potassium, leading to increased mortality.(54) Dalcetrapib,…”
Burkart, K. M., Manichaikul, A. W., Wilk, J. B., Ahmed, F. S., Burke, G. L., Enright, P., Hansel, N. N., Haynes, D., Heckbert, S. R., Hoffman, E. A., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00147612 · Cited by 73
“study on HDL and cardiovascular disease suggested no benefit[83] and large-scale randomized clinical trials of cholesterol ester transfer proteins, which raise HDL levels, have yet to show a benefit on clinical cardiovascular events[84,85].”
BackgroundBaseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K., Ivanovich, P. T., Kewalramani, R., Levey, A. S., Lewis, E. F., et al. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.04.008 · Cited by 66
O'Reilly, M. E., Dillon, E., Guo, W., Finucane, O. M., McMorrow, A. M., Murphy, A. M., Lyons, C. L., Jones, D., Ryan, M., Gibney, M. J., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020278 · Cited by 69
HDL mimetic CER-001 targets atherosclerotic plaques in patients
Zheng, K. H., van der Valk, F. M., Smits, L. P., Sandberg, M., Dasseux, J., Baron, R., Barbaras, R., Keyserling, C., Coolen, B. F., Nederveen, A. J., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.038 · Cited by 74
The Role of Emerging Risk Factors in Cardiovascular Outcomes
Lacey, B., Herrington, W. G., Preiss, D., Lewington, S., & Armitage, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0661-2 · Cited by 79
New lipid-lowering drugs: an update
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02867.x · Cited by 69
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Accounting for complexity in medical education: a model of adaptive behaviour in medicine
Woodruff, J. N. (2019) · Medical Education · doi:10.1111/medu.13905 · Cited by 76
Levin, M. G., Zuber, V., Walker, V. M., Klarin, D., Lynch, J., Malik, R., Aday, A. W., Bottolo, L., Pradhan, A. D., Dichgans, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053797 · Cited by 65
“51 The ongoing PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) Study will evaluate the impact of triglyceride-rich lipoprotein-lowering on major cardiovascular events with adjudicated PAD events as a secondary endpoint of the trial.”
Zhang, M., Charles, R., Tong, H., Zhang, L., Patel, M., Wang, F., Rames, M. J., Ren, A., Rye, K., Qiu, X., et al. (2015) · Scientific Reports · doi:10.1038/srep08741 · Cited by 69
How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 69
“These results may be attributable to the fact that torcetrapib activates the aldosterone system and increases the potassium concentration in the blood and blood pressure [73].”
BackgroundPro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins?
Vuilleumier, N., DAYER, J.-M., von Eckardstein, A., & Roux-Lombard, P. (2013) · Swiss Medical Weekly · doi:10.4414/smw.2013.13781 · Cited by 69
Kalil, R. S., Wang, J., de Boer, I. H., Mathew, R. O., Ix, J. H., Asif, A., Shi, X., & Boden, W. E. (2015) · Kidney International · doi:10.1038/ki.2014.383 · Cited by 68
Charles‐Schoeman, C., Lee, Y. Y., Shahbazian, A., Wang, X., Elashoff, D. A., Curtis, J. R., Navarro-Millán, I. Y., Yang, S., Chen, L., Cofield, S. S., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39833 · Cited by 69
“outcomes (15,16), thus strengthening the hypothesis”
HDL cholesterol and ASCVD risk stratification: A debate
Barter, P. J., & Genest, J. J. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.001 · Cited by 72
Self-citationAnacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
Gutstein, D. E., Krishna, R., Johns, D. G., Surks, H. K., Dansky, H. M., Shah, S., Mitchel, Y., Arena, J. P., & Wagner, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.271 · Cited by 76
Clerc, R. G., Stauffer, A., Weibel, F., Hainaut, E., Perez, A., Hoflack, J.-C., Benardeau, A. M., Pflieger, P., Garriz, J. M. R., Funder, J. W., et al. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833b1f8e · Cited by 66
Kjeldsen, E. W., Thomassen, J. Q., & Frikke‐Schmidt, R. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159063 · Cited by 76
Zoppini, G., Targher, G., Chonchol, M., Perrone, F., Lippi, G., & Muggeo, M. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.11.003 · Cited by 67
Inflammation, remodeling, and other factors affecting HDL cholesterol efflux
Ronsein, G. E., & Vaisar, T. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000382 · Cited by 71
Khoudary, S. R. E. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000432 · Cited by 73
Holleboom, A. G., Vergeer, M., Hovingh, G. K., Kastelein, J. J., & Kuivenhoven, J. A. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328306a043 · Cited by 64
Self-citationHegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“Thus, CETP has received considerable attention as a drug target, although 2 CETP inhibitors have failed in large CVD outcome trial.(103,104) Torcetrapib-treated individuals experienced increased CV events and mortality despite substantial reductions in LDL cholesterol,(103) putatively because of off-target increases i…”
BackgroundVery High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality
Liu, C., Dhindsa, D. S., Almuwaqqat, Z., Sun, Y. V., & Quyyumi, A. A. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.11.041 · Cited by 68
Helal, O., Berrougui, H., Loued, S., & Khalil, A. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512003856 · Cited by 63
“Nevertheless, the present study presents some limitations: (1) the design of the study lacks a control group; (2) the diet of the participants was not controlled.”
ResultDysfunctional High-Density Lipoprotein and Atherosclerosis
Ragbir, S. T., & Farmer, J. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0091-x · Cited by 67
“However, torcetrapib failed to demonstrate a reduction in cardiovascular events in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerosis Events (ILLUMINATE) trial despite a significant increase in HDL levels [29].”
BackgroundBelalcazar, L. M., Haffner, S. M., Lang, W., Hoogeveen, R. C., Rushing, J., Schwenke, D. C., Tracy, R. P., Pi‐Sunyer, F. X., Kriska, A. M., & Ballantyne and the Look AHEAD (Action for Health in Diabetes, C. M. (2013) · Obesity · doi:10.1002/oby.20431 · Cited by 63
“the subject of multiple intervention trials (5-8), with potential benefits”
BackgroundKopecky, C., Genser, B., Drechsler, C., Krane, V., Kaltenecker, C. C., Hengstschläger, M., März, W., Wanner, C., Säemann, M. D., & Weichhart, T. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06560714 · Cited by 63
Song, G., Liu, J., Zhao, Z., Yu, Y., Tian, H., Yao, S., Li, G., & Qin, S. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-8 · Cited by 63
“One of the important anti-atherogenic effects of HDL-C is to facilitate the efflux of cholesterol from peripheral tissues and transport it back to the liver in a process called RCT [15].”
BackgroundThe Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors
Vergeer, M., & Stroes, E. S. G. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.017 · Cited by 63
HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
Bhatt, A. B., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0554-1 · Cited by 73
Oshaghi, E. A., Goodarzi, M. T., Higgins, V., & Adeli, K. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1343274 · Cited by 68
Molecular regulation of plasma lipid levels during systemic inflammation and sepsis
Trinder, M., Boyd, J. H., & Brunham, L. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000577 · Cited by 62
HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk
Allard‐Ratick, M., Kindya, B., Khambhati, J., Engels, M. C., Sandesara, P. B., Rosenson, R. S., & Sperling, L. S. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319848214 · Cited by 67
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Nordestgaard, L. T., Christoffersen, M., Lauridsen, B. K., Afzal, S., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3728 · Cited by 61
Eliasson, B., Guðbjörnsdóttir, S., Zethelius, B., Eeg‐Olofsson, K., & Cederholm, J. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313494292 · Cited by 62
Airan-Javia, S. L., Wolf, R. L., Wolfe, M. L., Tadesse, M., Mohler, E., & Reilly, M. P. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.01.001 · Cited by 63
“5 (60–80) Male sex 17 (68) 19 (79) 18 (69) Race† White 21 (84) 23 (96) 16 (61) African American 4 (16) 1 (4) 9 (35) Hispanic 0 0 1 (4) Body mass index (kg/m2) 26.”
Riaz, H., Khan, S. U., Rahman, H., Shah, N. P., Kaluski, E., Lincoff, A. M., & Nissen, S. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318816495 · Cited by 61
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.